Variable | PFS | OS | ||||||
---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||
HR (95% CI) | P valuea | HR (95% CI) | P valuea | HR (95% CI) | P valuea | HR (95% CI) | P valuea | |
Age | 1.000 (0.986–1.014) | 0.980 | 0.993 (0.977–1.009) | 0.381 | 1.008 (0.987–1.029) | 0.480 | 0.996 (0.973–1.020) | 0.757 |
Sex (men vs. women) | 1.149 (0.830–1.590) | 0.404 | 1.520 (0.916–2.522) | 0.105 | 1.540 (0.992–2.393) | 0.055 | 1.776 (0.890–3.544) | 0.103 |
Smoking status (ever vs. never) | 0.907 (0.628–1.311) | 0.604 | 0.616 (0.363–1.044) | 0.072 | 1.299 (0.807–2.091) | 0.282 | 0.835 (0.405–1.722) | 0.626 |
ECOG PS (2 vs. 0-1) | 0.969 (0.523–1.796) | 0.921 | 1.019 (0.536–1.935) | 0.955 | 1.054 (0.454–2.447) | 0.903 | 1.281 (0.531–3.091) | 0.582 |
EGFR-TKI (erlotinib vs. gefitinib) | 0.828 (0.531–1.291) | 0.405 | 0.765 (0.448–1.307) | 0.327 | 1.862 (0.581–5.962) | 0.295 | 0.756 (0.357–1.603) | 0.466 |
EGFR-TKI (icotinib vs. gefitinib) | 0.652 (0.359–1.184) | 0.160 | 0.702 (0.362–1.361) | 0.295 | 1.917 (0.551–6.664) | 0.306 | 0.255 (0.063–1.037) | 0.056 |
Stage (IIIB vs. IV) | 0.552 (0.203–1.498) | 0.243 | 0.402 (0.119–1.356) | 0.142 | 0.878 (0.276–2.795) | 0.826 | 0.600 (0.144–2.506) | 0.483 |
EGFR mutation (exon 19 del vs. L858R mutation) | 0.705 (0.509–0.976) | 0.035 | 0.631 (0.432–0.920) | 0.017 | 0.878 (0.563–1.370) | 0.566 | 0.671 (0.397–1.133) | 0.135 |